CO2017011536A2 - Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo - Google Patents

Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo

Info

Publication number
CO2017011536A2
CO2017011536A2 CONC2017/0011536A CO2017011536A CO2017011536A2 CO 2017011536 A2 CO2017011536 A2 CO 2017011536A2 CO 2017011536 A CO2017011536 A CO 2017011536A CO 2017011536 A2 CO2017011536 A2 CO 2017011536A2
Authority
CO
Colombia
Prior art keywords
antibody
combination
death
composition
compositions
Prior art date
Application number
CONC2017/0011536A
Other languages
English (en)
Inventor
Vikram SADINENI
Yong Quan
Wallace Kaserer
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55809254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017011536(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2017011536A2 publication Critical patent/CO2017011536A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden una combinación de un agente contra el cáncer que es un primer anticuerpo y un segundo anticuerpo. En algunas modalidades, el primer anticuerpo es un anticuerpo anti-muerte programada-1 (PD-1). En ciertas modalidades, la composición es una formulación de dosis fija. En ciertas modalidades, la composición se administra como una dosis uniforme. También un kit para tratar un sujeto afectado con una enfermedad, en donde el kit comprende una dosis de cualquier composición descrita en la presente e instrucciones para usar la composición en cualquiera de los métodos descritos para tratar una enfermedad.
CONC2017/0011536A 2015-04-17 2017-11-10 Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo CO2017011536A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562149325P 2015-04-17 2015-04-17
US201562265268P 2015-12-09 2015-12-09
US201562269000P 2015-12-17 2015-12-17
US201662303855P 2016-03-04 2016-03-04
PCT/US2016/027913 WO2016168716A1 (en) 2015-04-17 2016-04-15 Compositions comprising a combination of an anti-pd-1 antibody and another antibody

Publications (1)

Publication Number Publication Date
CO2017011536A2 true CO2017011536A2 (es) 2018-02-09

Family

ID=55809254

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011536A CO2017011536A2 (es) 2015-04-17 2017-11-10 Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo

Country Status (32)

Country Link
US (4) US20160304607A1 (es)
EP (2) EP3738610A1 (es)
JP (3) JP6949718B2 (es)
KR (1) KR20170138477A (es)
CN (2) CN107743401B (es)
AU (2) AU2016249395B2 (es)
BR (1) BR112017021688A2 (es)
CA (1) CA2982839A1 (es)
CL (1) CL2017002636A1 (es)
CO (1) CO2017011536A2 (es)
CY (1) CY1123397T1 (es)
DK (1) DK3283107T3 (es)
EA (1) EA201792273A1 (es)
ES (1) ES2813580T3 (es)
HK (1) HK1247099A1 (es)
HR (1) HRP20201334T1 (es)
HU (1) HUE050894T2 (es)
IL (2) IL255072B (es)
LT (1) LT3283107T (es)
MA (1) MA53243A (es)
MX (2) MX2017013270A (es)
MY (1) MY188749A (es)
PE (1) PE20180394A1 (es)
PH (1) PH12017501774A1 (es)
PL (1) PL3283107T3 (es)
PT (1) PT3283107T (es)
RS (1) RS60753B1 (es)
SG (2) SG11201708223QA (es)
SI (1) SI3283107T1 (es)
TN (1) TN2017000440A1 (es)
TW (3) TWI733664B (es)
WO (1) WO2016168716A1 (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
MX2016014189A (es) 2014-05-13 2017-05-04 Medimmune Ltd Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
EP3498295A1 (en) 2014-05-28 2019-06-19 Agenus Inc. Anti-gitr antibodies and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CR20170096A (es) 2014-08-12 2017-06-15 Alligator Bioscience Ab Tratamientos conjuntos con anticuerpos anti cd40
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
US20160304607A1 (en) 2015-04-17 2016-10-20 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-pd-1 antibody and another antibody
KR20170140316A (ko) 2015-04-28 2017-12-20 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN108368170B (zh) 2015-07-13 2022-04-15 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
US10544224B2 (en) * 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
MA42626A (fr) 2015-08-11 2018-06-20 Open Monoclonal Tech Inc Nouveaux anticorps anti-pd-1
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
KR20180083944A (ko) 2015-12-02 2018-07-23 아게누스 인코포레이티드 항체 및 이의 사용 방법
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
EP3399989B1 (en) 2015-12-16 2023-08-09 Merck Sharp & Dohme LLC Anti-lag3 antibodies and antigen-binding fragments
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
DK3458478T3 (da) 2016-05-18 2021-03-22 Boehringer Ingelheim Int Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
DK3551629T3 (da) * 2016-12-08 2024-02-12 Lixte Biotechnology Inc Oxabicycloheptaner til modulering af immunrespons
DK3565844T3 (da) * 2017-01-09 2023-05-01 Tesaro Inc Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
IL308805A (en) * 2017-02-21 2024-01-01 Regeneron Pharma Anti-PD-1 antibodies for the treatment of lung cancer
EP3600395A4 (en) 2017-03-23 2021-05-05 The General Hospital Corporation BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
EA201991912A1 (ru) * 2017-03-29 2020-03-10 Селджин Корпорейшн Составы, содержащие pd-1-связывающие белки, и способы их получения
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
BR112019021680A2 (pt) 2017-04-20 2020-05-12 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo-fármaco anti-cd25??
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP2020518598A (ja) * 2017-05-02 2020-06-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
TW201842929A (zh) * 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
EP3625260A1 (en) * 2017-05-16 2020-03-25 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
US20190135905A1 (en) * 2017-06-16 2019-05-09 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
SG10201913147WA (en) 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
JP7399845B2 (ja) * 2017-08-18 2023-12-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 試料マトリックスにおいてタンパク質変異体を分析するための画像キャピラリー等電点電気泳動法
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
CA3074565A1 (en) * 2017-09-05 2019-03-14 Merck Sharp & Dohme Corp. Compounds for reducing the viscosity of biological formulations
JP2020532991A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
WO2019073069A1 (en) * 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
CN111213059B (zh) * 2017-11-06 2024-01-09 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019108951A1 (en) * 2017-12-01 2019-06-06 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibiting dhhc-type palmitoyltransferases for cancer treatment
WO2019143607A1 (en) * 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
WO2019195452A1 (en) * 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
AU2019272838A1 (en) 2018-05-23 2020-11-26 Adc Therapeutics Sa Molecular adjuvant
WO2019240872A1 (en) * 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
US20210338813A1 (en) * 2018-10-19 2021-11-04 Bristol-Myers Squibb Company Combination Therapy for Melanoma
CN113302204A (zh) * 2018-11-05 2021-08-24 默沙东公司 用于治疗癌症的抗tigit抗体的给药方案
EP3880709A4 (en) * 2018-11-05 2022-07-27 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR THE TREATMENT OF CANCER
WO2020094744A1 (en) * 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
EP3876978A4 (en) 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE
MX2021005394A (es) * 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
EP4008346A4 (en) * 2019-07-18 2022-10-19 Delta-Fly Pharma, Inc. AGENT FOR INCREASING THE EFFECT OF AN ANTICONCER AGENT
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
EP4074338A4 (en) * 2019-12-13 2024-03-06 Samsung Bioepis Co., Ltd. STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION
EP4076385A1 (en) * 2019-12-20 2022-10-26 Formycon AG Formulations of anti-pd1 antibodies
CN115397859A (zh) 2020-01-30 2022-11-25 Ona疗法有限公司 治疗癌症和癌症转移的联合疗法
KR20220149740A (ko) * 2020-03-05 2022-11-08 머크 샤프 앤드 돔 엘엘씨 Pd-1 길항제, ctla4 길항제 및 렌바티닙 또는 그의 제약상 허용되는 염의 조합물을 사용하여 암을 치료하는 방법
IL295979A (en) 2020-03-06 2022-10-01 Ona Therapeutics S L Anti-cd36 antibodies and their use for cancer treatment
US20230285555A1 (en) * 2020-04-17 2023-09-14 Dingfu Biotarget, Co., Ltd. Preparation specifically bound with cd137 and use thereof
JP2023529234A (ja) * 2020-06-19 2023-07-07 神州細胞工程有限公司 組換え抗ｐｄ－１モノクローナル抗体のための安定な製剤
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
WO2022010988A1 (en) * 2020-07-08 2022-01-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ctla-4 antibodies
EP4008345A1 (en) * 2020-12-03 2022-06-08 Hexal AG Novel formulations for antibodies
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
TW202308692A (zh) * 2021-04-27 2023-03-01 俄羅斯聯邦商拜奧卡德聯合股份公司 包含帕博利珠單抗（ｐｅｍｂｒｏｌｉｚｕｍａｂ）的藥學組成物及其用途
WO2022263632A1 (en) * 2021-06-18 2022-12-22 Alligator Bioscience Ab Novel combination therapies and uses thereof
TW202317185A (zh) * 2021-06-18 2023-05-01 美商健臻公司 抗ＴＧＦ－β抗體配製品及其用途
KR20240028506A (ko) * 2021-07-02 2024-03-05 기가젠, 인코포레이티드 항-ctla-4 결합 단백질 및 이의 사용 방법
CA3226281A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023235847A1 (en) * 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP2283867B1 (en) 1999-06-25 2014-05-21 ImmunoGen, Inc. Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
ES2654064T3 (es) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
EP1539237A4 (en) 2002-07-30 2006-05-24 Bristol Myers Squibb Co HUMANIZED ANTIBODIES AGAINST HUMAN 4-1BB
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
MXPA05013923A (es) 2003-07-02 2006-08-11 Univ Genova Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia.
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
ATE531733T1 (de) 2005-01-06 2011-11-15 Novo Nordisk As Kir-bindende wirkstoffe und verfahren zu ihrer verwendung
SI1865986T1 (sl) 2005-03-08 2016-05-31 Pfizer Products Inc. Sestavki protitelesa proti CTLA-4
CN101193917A (zh) * 2005-03-08 2008-06-04 法玛西雅厄普约翰有限责任公司 抗-MAdCAM抗体组合物
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2322557B1 (en) 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
JP5478261B2 (ja) 2007-01-11 2014-04-23 ノヴォ ノルディスク アクティーゼルスカブ 抗ｋｉｒ抗体、製剤、およびその使用
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
WO2009045957A1 (en) 2007-10-01 2009-04-09 Medarex, Inc. Human antibodies that bind mesothelin, and uses thereof
CA2706926A1 (en) 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
MX2010012579A (es) * 2008-05-29 2010-12-20 Squibb Bristol Myers Co Metodos para predecir respuesta de pacientes a modulacion de la via co-estimuladora.
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
KR20110096553A (ko) * 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
CA3067609A1 (en) 2009-09-03 2011-03-10 Merck Sharp & Dohme Corp. Anti-gitr antibodies
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
KR101958753B1 (ko) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. 인간 ｃｄ27에 결합하는 항체 및 이의 용도
TWI664191B (zh) 2010-11-22 2019-07-01 天賜製藥公司 Ｎｋ細胞調節治療及治療血液惡性疾病之方法
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
JP6014116B2 (ja) * 2011-03-31 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN103717619B (zh) 2011-05-25 2018-11-13 因内特制药股份有限公司 治疗发炎及自体免疫疾病之抗-kir抗体
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
HUE043001T2 (hu) 2011-11-09 2019-07-29 Bristol Myers Squibb Co Hematológiai malignómák kezelése anti-CXCR4 antitesttel
CA2856895C (en) 2011-11-28 2021-10-26 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
CN104470949A (zh) 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
KR101549637B1 (ko) 2012-06-08 2015-09-03 국립암센터 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
AU2013278843A1 (en) * 2012-06-21 2014-03-27 Compugen Ltd. LSR antibodies, and uses thereof for treatment of cancer
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
NZ631405A (en) * 2012-10-02 2017-01-27 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
KR101809151B1 (ko) * 2013-07-18 2017-12-15 (주)앗코스텍 키레놀 또는 희첨 추출물을 포함하는 골다공증 예방, 개선 또는 치료용 조성물
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3498295A1 (en) 2014-05-28 2019-06-19 Agenus Inc. Anti-gitr antibodies and methods of use thereof
EP3610924B1 (en) 2014-06-06 2021-11-03 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US20160304607A1 (en) 2015-04-17 2016-10-20 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-pd-1 antibody and another antibody

Also Published As

Publication number Publication date
EA201792273A1 (ru) 2018-04-30
DK3283107T3 (da) 2020-08-31
TN2017000440A1 (en) 2019-04-12
LT3283107T (lt) 2020-09-10
CN113577264A (zh) 2021-11-02
IL255072A0 (en) 2017-12-31
TW202335681A (zh) 2023-09-16
BR112017021688A2 (pt) 2018-08-14
EP3738610A1 (en) 2020-11-18
SG11201708223QA (en) 2017-11-29
PE20180394A1 (es) 2018-02-28
TW201709930A (zh) 2017-03-16
MX2017013270A (es) 2018-01-25
MY188749A (en) 2021-12-28
US11612654B2 (en) 2023-03-28
US20160304607A1 (en) 2016-10-20
SI3283107T1 (sl) 2020-10-30
JP6949718B2 (ja) 2021-10-13
IL289600A (en) 2022-03-01
SG10201912035YA (en) 2020-02-27
CN107743401A (zh) 2018-02-27
HRP20201334T1 (hr) 2020-11-27
RS60753B1 (sr) 2020-10-30
HUE050894T2 (hu) 2021-01-28
EP3283107A1 (en) 2018-02-21
TW202206101A (zh) 2022-02-16
TWI787880B (zh) 2022-12-21
WO2016168716A1 (en) 2016-10-20
EP3283107B1 (en) 2020-05-27
US20200197518A1 (en) 2020-06-25
CL2017002636A1 (es) 2018-06-01
HK1247099A1 (zh) 2018-09-21
MA53243A (fr) 2021-06-23
PH12017501774A1 (en) 2018-03-19
PT3283107T (pt) 2020-08-31
US10512689B2 (en) 2019-12-24
US20240091354A1 (en) 2024-03-21
KR20170138477A (ko) 2017-12-15
JP2022008479A (ja) 2022-01-13
PL3283107T3 (pl) 2020-12-14
CN107743401B (zh) 2021-08-24
JP2024009946A (ja) 2024-01-23
CY1123397T1 (el) 2021-12-31
AU2022204037A1 (en) 2022-06-30
IL255072B (en) 2022-02-01
AU2016249395A1 (en) 2017-10-19
US20170143827A1 (en) 2017-05-25
TWI733664B (zh) 2021-07-21
CA2982839A1 (en) 2016-10-20
AU2016249395B2 (en) 2022-04-07
ES2813580T3 (es) 2021-03-24
JP2018513159A (ja) 2018-05-24
MX2022003572A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
DOP2017000261A (es) Derivados de ciclohexano sustituido con amido
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
BR112016017897A8 (pt) uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
BR112018067923A2 (pt) métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
AR117405A1 (es) Uso de conjugados anticuerpo-fármaco que comprenden agentes que alteran la tubulina para tratar tumores sólidos
AR104310A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti-pd-1 y otro anticuerpo